Pharmaceuticals Government Tenders in Czech Republic

Registration, quality assurance and the shape of a medicines contract

A medicines tender is decided on quality assurance before it is decided on price. Bidders must show that the product is authorised or registered for use in the destination market, that it is manufactured at a site holding current good manufacturing practice certification, and -- for many donor-funded and essential medicines programmes -- that the product or its manufacturer appears on a recognised prequalification list. These are documentary conditions of admissibility assessed against the specific product and manufacturing site offered, and a change of site after award is a contractual event, not an administrative one.

Products are specified by international non-proprietary name, strength and dosage form so that generics compete openly, with pharmacopoeial standards cited for quality. Delivery conditions carry as much weight as the product: a minimum proportion of shelf life remaining on arrival, batch certificates of analysis, tamper-evident and correctly labelled packaging in the required language, and unbroken cold chain with temperature monitoring for products that need it. A consignment that arrives with too little shelf life left is routinely rejected at the buyer's cost to the supplier.

The commercial structure is usually a framework at agreed unit prices with call-offs against forecast rather than firm volume, because demand depends on disease patterns and programme funding. That places emphasis on lead times, on the supplier's obligation to hold or replenish stock, and on what happens in a shortage -- allocation, substitution and notification terms are increasingly explicit. Recall capability is tested rather than assumed: buyers ask how quickly a batch can be traced and withdrawn from every facility it reached.

This section describes how this category is bought generally, across the public buyers that publish it. The figures elsewhere on this page are measured for this market alone.

Who buys pharmaceuticals in Czech Republic?

GlobalGov holds 565 pharmaceuticals records from 147 distinct buying organisations in Czech Republic. The most frequent publishers are Fakultní nemocnice Brno (43 records); Univerzita Palackého v Olomouci (18 records); Ústav organické chemie a biochemie AV ČR, v. v. i. (18 records); Lesy České republiky, s.p. (15 records); Ústav organické chemie a biochemie AV ČR, v.v.i. (15 records); Fakultní nemocnice Brno (14 records). Between them the 6 largest account for 22% of everything published, so buying here is spread across many separate authorities.

What are pharmaceuticals contracts worth in Czech Republic?

418 of the 565 records publish a contract value. The median is $526,900 and the largest single published value is $704.0M. By size, 49 under $100k, 239 between $100k and $1M, 100 between $1M and $10M, 30 above $10M. The remaining 147 publish no value at all, so every figure here describes the priced subset only, and values are as stated by the buyer rather than as finally awarded.

How long do bidders get to respond to pharmaceuticals tenders in Czech Republic?

Across the 231 Czech Republic pharmaceuticals notices that publish both a publication date and a closing date, the median response window is 32 days. A quarter of them allowed 30 days or fewer and a quarter stayed open for more than 34. Short turnarounds are the exception rather than the rule here: only 1 (0.4%) closed within a fortnight of being published.

How often are pharmaceuticals tenders published in Czech Republic?

Czech Republic publishes about 11 notices a month in this category, 132 in the last twelve months. That is 39% more than the 95 published in the twelve months before that. Over the last three years there were 325, spread across 58 separate months of activity since 28 July 2016. March is historically the busiest month. The most recent was published 15 September 2026.

How does Czech Republic compare with other pharmaceuticals markets?

Among the 39 countries where GlobalGov holds a comparable pharmaceuticals market, Czech Republic ranks 11th by number of records. The largest is Germany (4,115 records against 565 here). Within Czech Republic itself, pharmaceuticals is the 19th largest of the 61 procurement categories tracked here.

Where do the Czech Republic pharmaceuticals records on this page come from?

These 565 records are collected from 1 official source: TED (565). GlobalGov is an independent aggregator and is not affiliated with any of them; each record links back to the notice on its issuing portal. The set is rebuilt nightly, and the counts on this page were taken on 2026-10-01.

Open Pharmaceuticals tenders in Czech Republic

Showing 10 of the 26 notices open in this category today. Openness uses the same definition as the Czech Republic market page: active, not marked awarded, cancelled, closed or expired, and either closing in the future or published within the last 90 days with no stated closing date.

Other procurement categories in Czech Republic

Pharmaceuticals procurement in other markets